logo-loader
viewOpen Orphan PLC

Value the Markets Webinar

/**/ sup{font-size:80%}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .al{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.al{}p.be{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.bf{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.bg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.ba{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.bh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}span.ay{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.bi{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; text-align: center}p.bj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} span.av{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.k,li.k,div.k{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.at{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.bk{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify; text-decoration: underline}span.bc{font-size:11.0pt; font-family:"Calibri","sans-serif"}a.ar{font-weight: bold}.ap{text-decoration: underline}span.aq{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.bl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; text-align: justify} p.bn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}p.bo{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.bp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify} /**/
RNS Number : 9383Q
Open Orphan PLC
24 October 2019
 

24 October 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Value the Markets Webinar

Open Orphan's Maurice Treacy Hosts Value the Markets Webinar

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company's Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30th October 2019 at 19:00 (UK time).

Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the Company's Genomic Health Data platform, Europe's first rare disease, advocacy-led genomic database. Maurice will also discuss how and why it is now so important for pharmaceutical companies to have access to patient data when developing new drugs.

For those wishing to join, the webinar will be available through webcast or dial-in facilities via the details provided below:

Webcast URL Link:

https://vtm.clickmeeting.com/orph 

Dial-in details:

UK dial-in number: +44 (20) 7048 4146

Irish dial-in number: +353 (76) 680 3062

 

Participant PIN: 214883#

 

When prompted, please provide participant's pin code followed by # key

 

Enquiries:

Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAMJBLTMBJTBRL

Quick facts: Open Orphan PLC

Price: 5.4

Market: AIM
Market Cap: £13.75 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

2 days, 20 hours ago

RNS

Form 8.3 - Open Orphan PLC

13 hours, 20 minutes ago

Form 8.3 - Open Orphan

1 day, 13 hours ago

Form 8.5 (EPT/NON-RI)

1 day, 18 hours ago

Form 8.3 - Open Orphan

1 day, 18 hours ago

Form 8 (OPD)

1 day, 23 hours ago

Form 8 (DD) Open Orphan plc

2 days, 13 hours ago

Form 8.5 (EPT/NON-RI)

2 days, 18 hours ago